Pharma Journalist -

Pierre Fabre announced that the European Commission (EC) has approved BRAFTOVI (encorafenib) in combination with cetuximab (marketed as Erbitux) for the treatment of adult patients with…
Read More...

AgeX Therapeutics, Inc. and ImStem Biotechnology, Inc. announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s…
Read More...

FSD Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of…
Read More...

PharmAbcine announced that the company entered into a license agreement with Wincal Biopharm, a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the commercial value…
Read More...

Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with…
Read More...

We are excited to release the agenda for the Innate Immune Stimulating Therapies Summit, running virtually on Wednesday, July 22 at 09.00 Eastern Time. Join the first…
Read More...

JAK inhibitors have been hotly pursued by the biopharmaceutical industry as new players in the field of immune-mediated diseases. This year, and with COVID-19 on the top of the agenda…
Read More...

Predictive Oncology Inc. announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of…
Read More...

Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced that it has entered into two strategic…
Read More...

AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation…
Read More...